

D<sup>1</sup>  
Cont

acids 24-34 of SEQ ID NO:2; Framework #2: amino acids 35-49 of SEQ ID NO:2;  
CDR-2: amino acids 50-56 of SEQ ID NO:2; Framework #3: amino acids 57-88 of  
SEQ ID NO:2; CDR-3: amino acids 89-97 of SEQ ID NO:2; and Framework #4:  
amino acids 98-107 of SEQ ID NO:2)--~~[and]~~

lines 2-3, delete "(Amino acids 1-118 of SEQ ID NO:4; Fig. 3B)" and insert therein

D<sup>2</sup>

--, Fig. 3B (Framework #1: amino acids 1-30 of SEQ ID NO:4; CDR-1: amino  
acids 31-35 of SEQ ID NO:4; Framework #2: amino acids 36-49 of SEQ ID NO:4;  
CDR-2: amino acids 50-66 of SEQ ID NO:4; Framework #3: amino acids 67-98 of  
SEQ ID NO:4; CDR-3: amino acids 99-107 of SEQ ID NO:4; and Framework #4:  
amino acids 108-118 of SEQ ID NO:4)--.

#### Remarks

The Examiner describes two purported errors in the Sequence Listing as filed on May 6, 1998 (Paper No. 11). The first is that the amino acids listed in Fig. 3A and Fig. 3B lack SEQ ID NOs and do not appear to be in the Sequence Listing. The specification as originally filed describes collectively that the amino acids are located in SEQ ID NO:2 and 4, respectively. The amendment submitted above further clarifies that the amino acid sequences are located within SEQ ID NO:2 and 4, and gives the exact positions of the amino acids within each sequence. Therefore, the sequences are recited in the Sequence Listing.

The Examiner further states that the claims do not recite SEQ ID NOS for the CDR sequences. The claims describe that the CDR amino acids are embedded within SEQ ID NO:2 or SEQ ID NO:4, and therefore, are recited in the Sequence Listing.

The second error noted by the Examiner is that there is a discrepancy in Figure 1 and SEQ ID NO:2 at amino acid position 81. The nucleotides GAA in Figure 1 were incorrectly

translated as Glu instead of Gly. Applicants respectfully direct the Examiner's attention to page 9, lines 4-5, and page 115, lines 4-12, where the Gly-Glu translation error in Fig. 1 and Fig. 3A is discussed fully.

The Gly-Glu translation error is typographical in nature, and its correction does not constitute new matter in the Sequence Listing.

Applicants believe all issues raised in the communication from the Examiner have been addressed, and respectfully request substantive examination of this application, especially in view of telephone calls with the Examiner and submission of preliminary amendments dated October 8, 1998, and July 30, 1998.

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our **Deposit Account No. 03-1952** (304142000321) However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,


Dated: January 5, 1999

By:



Catherine M. Polizzi  
Registration No. 40,130

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5651  
Facsimile: (650) 494-0792



Application No. 08/766 350

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The Sequence in spec is not same as that in Sequence Listing. Sequences lack Seq ID Nos

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**